Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

A groundbreaking study is testing new ways to bring HIV prevention and PrEP to men whose work keeps them constantly on the road.

Tennessee Gov. Bill Lee said the state had applied for a federal grant funding for rural healthcare, hoping for a piece of ...

It's a balmy afternoon in Mtubatuba, in northern KwaZulu-Natal (KZN), and the local taxi rank is abuzz with activity. Drivers are calling out their routes while others rev their engines, getting ready ...

Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market ...

Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM ESTCompany ParticipantsTony Wood - Chief Scientific Officer and Head ...

CoapTech, a medical technology company advancing ultrasound?guided solutions for enteral access, today announced that its Board of Directors has appointed Brad Kreger as Chief Executive Officer.

Q3 2025 Management View Daniel O'Day, Chairman & CEO, stated that "our third quarter earnings underscore the growing momentum you're seeing from Gilead today, which is driven by our strong portfolio ...

Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...

Introduction Saskatchewan is facing a public health crisis driven by high rates of HIV, syphilis and hepatitis C virus (HCV) infections, particularly among people who use drugs. Injection drug use is ...

At the booth of Gilead Sciences, Lenacapavir, to be used as the world's only twice-yearly, long-acting injectable for HIV ...

The 24th International Conference on Nanoimprint and Nanoprint Technologies (NNT 2025), concluded in Dana Point, California, celebrating the 30th anniversary of Nanoimprint Lithography (NIL), or ...